The TGA has approved a new hepatitis C treatment, Gilead Sciences, Australia New Zealand, today announced. Harvoni (ledipasvir/ sofosbuvir) is the first daily single tablet regimen for the treatment of genotype one chronic hepatitis C (HCV) in adults. In clinical trials, it was shown that up to 99% of patients with HCV genotype one taking
This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.